Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature

Elavia,Zenia; Jimenez,Victoria; Lockhart,Roxanne; Muha,Allison; Kazamel,Mohamed

doi:10.3892/mi.2024.210

Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature

Authors:
- Zenia Elavia
- Victoria Jimenez
- Roxanne Lockhart
- Allison Muha
- Mohamed Kazamel
View Affiliations

Affiliations: Department of Neurology, University of Alabama, Birmingham, AL 35294, USA
Published online on: December 3, 2024 https://doi.org/10.3892/mi.2024.210
Article Number: 11
Copyright : © Elavia et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the ability of the immune system to combat malignancies. Nivolumab and cemiplimab, monoclonal antibodies targeting programmed cell death protein 1, have exhibited notable therapeutic efficacy; however, they are associated with immune‑related adverse events (irAEs). The present study describes the cases of 2 patients, a 71‑year‑old male with metastatic esophageal adenocarcinoma and a 66‑year‑old female with metastatic squamous cell carcinoma who developed acute/subacute onset rapidly progressive myositis/myasthenia gravis (MG) following treatment with nivolumab and cemiplimab. Both patients had negative MG antibody panels and the first had uninformative electrodiagnostic testing, rendering the diagnosis challenging. Additionally, 1 patient had myocarditis and the other had hepatitis. The mechanisms of ICI‑induced myositis/MG remain unclear. Early recognition and intervention are vital for the prevention of severe morbidity and mortality. Treatment strategies, including the termination of the offending ICI medication, steroids, intravenous immunoglobulin (IVIG) and plasma exchange, should be tailored based on individual patient responses, and physicians should not hesitate to commence IVIG or plasma exchange once the diagnosis is established.. These cases underscore the importance of vigilance for myositis/MG in patients treated with ICIs, even with uninformative serological and electrodiagnostic testing, and the need for collaboration between multiple disciplines in managing complex irAEs including the associated myocarditis and hepatitis.

View Figures

View References

1	Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018.PubMed/NCBI View Article : Google Scholar
2	Tahir N, Mahboob A, Piao X, Ying G, Shrestha J, Sherchan R and Zahra F: Nivolumab, a Double-Edged Sword: A case report of nivolumab-induced myasthenia gravis. J Med Cases. 12:424–428. 2021.PubMed/NCBI View Article : Google Scholar
3	Wilgenhof S and Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 22:991–993. 2011.PubMed/NCBI View Article : Google Scholar
4	Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H and Mauermann ML: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 74:1216–1222. 2017.PubMed/NCBI View Article : Google Scholar
5	Hottinger AF: Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 29:806–812. 2016.PubMed/NCBI View Article : Google Scholar
6	Haugh AM, Probasco JC and Johnson DB: Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 19:479–488. 2020.PubMed/NCBI View Article : Google Scholar
7	Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, et al: Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature. J Immunother Cancer. 7(319)2019.PubMed/NCBI View Article : Google Scholar
8	Weaver JM, Dodd K, Knight T, Chaudhri M, Khera R, Lilleker JB, Roberts M, Lorigan P and Cooksley T: Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: A case series. Support Care Cancer. 31(518)2023.PubMed/NCBI View Article : Google Scholar
9	Grob D, Brunner N, Namba T and Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve. 37:141–149. 2008.PubMed/NCBI View Article : Google Scholar
10	Gummi RR, Kukulka NA, Deroche CB and Govindarajan R: Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 60:693–699. 2019.PubMed/NCBI View Article : Google Scholar
11	Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, et al: Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 66:1334–1338. 2009.PubMed/NCBI View Article : Google Scholar
12	Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, Lavertu P and Yao M: Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. Am J Otolaryngol. 39:642–645. 2018.PubMed/NCBI View Article : Google Scholar
13	Kao JC, Brickshawana A and Liewluck T: Neuromuscular complications of programmed cell death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep. 18(63)2018.PubMed/NCBI View Article : Google Scholar
14	Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, et al: Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 107:1055–1058. 2016.PubMed/NCBI View Article : Google Scholar
15	Chen YH, Liu FC, Hsu CH and Chian CF: Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report. Medicine (Baltimore). 96(e7350)2017.PubMed/NCBI View Article : Google Scholar
16	Fazel M and Jedlowski PM: Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Reports Immunol. 2019(2539493)2019.PubMed/NCBI View Article : Google Scholar
17	Liao B, Shroff S, Kamiya-Matsuoka C and Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 16:589–593. 2014.PubMed/NCBI View Article : Google Scholar
18	Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR and Sosman JA: Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 33:e122–e124. 2015.PubMed/NCBI View Article : Google Scholar
19	Loochtan AI, Nickolich MS and Hobson-Webb LD: Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 52:307–308. 2015.PubMed/NCBI View Article : Google Scholar
20	Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M and Ando Y: Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 78:119–122. 2016.PubMed/NCBI
21	Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ and Zappia M: Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve. 54:507–509. 2016.PubMed/NCBI View Article : Google Scholar
22	Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R and Uhara H: Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 46:86–88. 2016.PubMed/NCBI View Article : Google Scholar
23	Polat P and Donofrio PD: Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve. 54(507)2016.PubMed/NCBI View Article : Google Scholar
24	Chang E, Sabichi AL and Sada YH: Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother. 40:114–116. 2017.PubMed/NCBI View Article : Google Scholar
25	Chen JH, Lee KY, Hu CJ and Chung CC: Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review. Medicine (Baltimore). 96(e9262)2017.PubMed/NCBI View Article : Google Scholar
26	Veccia A, Kinspergher S, Grego E, Peterlana D, Berti A, Tranquillini E and Caffo O: Myositis and myasthenia during nivolumab administration for advanced lung cancer: A case report and review of the literature. Anticancer Drugs. 31:540–544. 2020.PubMed/NCBI View Article : Google Scholar
27	Jeyakumar N, Etchegaray M, Henry J, Lelenwa L, Zhao B, Segura A and Buja LM: The terrible triad of checkpoint inhibition: A case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Reports Immunol. 2020(5126717)2020.PubMed/NCBI View Article : Google Scholar
28	Canino F, Pugliese G, Baldessari C, Greco S, Depenni R and Dominici M: Cemiplimab- and nivolumab-induced myasthenia gravis: Two clinical cases. Tumori. 107:NP123–NP126. 2021.PubMed/NCBI View Article : Google Scholar
29	Bawek SJ, Ton R, McGovern-Poore M, Khoncarly B and Narvel R: Nivolumab-Induced myasthenia gravis concomitant with myocarditis, myositis, and hepatitis. Cureus. 13(e18040)2021.PubMed/NCBI View Article : Google Scholar